Sueta Aiko, Yamamoto Yutaka, Iwase Hirotaka
Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, 1-1-1, Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
Cancer Drug Resist. 2019 Sep 19;2(3):847-861. doi: 10.20517/cdr.2019.17. eCollection 2019.
Despite several advances in targeted therapies for breast cancer, breast-cancer-associated death remains high in women. This is partially due to the lack of reliable markers predicting metastatic disease or recurrence after initial therapy. Recent research into the clinical validity of circulating cancer-specific biomarkers as a "liquid biopsy" is of growing interest. Of these, exosomal microRNAs (miRNAs) are promising candidate biomarkers for clinical use in breast cancer. In addition to their diagnostic value, exosomal miRNAs play an important role in predicting clinical outcome or treatment response. In this review, it is focused on the findings concerning exosomal miRNAs in relation to disease detection, prognostic impact and therapeutic effect in breast cancer, and discuss their clinical utility.
尽管乳腺癌的靶向治疗取得了多项进展，但女性乳腺癌相关死亡率仍然很高。这部分是由于缺乏可靠的标志物来预测转移性疾病或初始治疗后的复发情况。最近对循环癌症特异性生物标志物作为“液体活检”的临床有效性的研究越来越受到关注。其中，外泌体微小RNA（miRNA）是乳腺癌临床应用中有前景的候选生物标志物。除了具有诊断价值外，外泌体miRNA在预测临床结果或治疗反应方面也发挥着重要作用。在这篇综述中，重点关注了与乳腺癌疾病检测、预后影响和治疗效果相关的外泌体miRNA的研究结果，并讨论了它们的临床应用价值。
